IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
BioNTech RNA Pharmaceuticals GmbH v CureVac SE [2023] APO 36
Patent Application: 2016251687
Title:RNA containing composition for treatment of tumor diseases
Patent Applicant: CureVac SE
Opponent: BioNTech RNA Pharmaceuticals GmbH
Delegate: L. F. McCaffery
Decision Date: 16 June 2023
Hearing Date: 11 April 2023, by videoconference
Catchwords: PATENTS – compositions comprising mRNA – consideration of allowability of amendments under subsections 102(1) and 102(2)(b) – whether the amendments extend beyond the disclosure as filed – whether, as a result of the amendments, the claims are not clear and not supported – opposition unsuccessful – amendments are allowable – costs awarded.
Representation: Patent attorney for the applicant: Allens Patent & Trade Mark Attorneys
The Opponent did not appear or provide submissions for the hearing.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2016251687
Title:RNA containing composition for treatment of tumor diseases
Patent Applicant: CureVac SE
Date of Decision: 16 June 2023
DECISION
The amendments are allowable. The opposition is unsuccessful.
Costs according to Schedule 8 are awarded against the Opponent, BioNTech RNA Pharmaceuticals GmbH
REASONS FOR DECISION
The present matter relates to Australian Application 2016251687 (the application) in the name of CureVac SE (the Applicant) and an opposition to an amendment under s104(4) of the Patents Act 1990 (Cth) (the Act) by BioNTech RNA Pharmaceuticals GmbH (the Opponent).
The application was filed as International Patent Application PCT/EP2016/059109 on 22 April 2016 and published as WO2016/170176 on 27 October 2016. The application entered the national phase in Australia on 3 August 2017. The application was advertised as accepted on 11 June 2020. A notice of opposition to the grant of the patent under s59 of the Act was filed on 11 September 2020 (the S59 opposition).
The Applicant filed a request to amend the specification on 20 July 2021 (the amendment). Leave to amend was granted and the application for amendment advertised for opposition on 2 September 2021. A notice of opposition to the amendment was filed by the Opponent on 1 November 2021 (the S104 opposition). The present determination relates to the S104 opposition.
A statement of grounds and particulars (SGP) was filed on 1 December 2021. Both parties filed evidence in the opposition. Evidence in Support was completed on 15 February 2022 and consisted of the following declarations:
Cornelis J. M. Melief, dated 14 February 2022, and exhibits CJMM-12 to CJMM-14 (Melief 2)[1]
Mark Edward Wickham, dated 15 February 2022, and exhibits MEW-1 to MEW-6 (Wickham)
[1] Professor Melief had filed an earlier declaration in the S59 Opposition. I have included it in the present numbering of declarations as Melief 1.
On 21 April 2022 the Applicant requested a direction by the Commissioner that the time to file their Evidence in Answer (EIA) be extended. They subsequently filed their evidence on 20 May 2022. This consisted of a declaration by Colin W. Pouton, dated 20 May 2022,…
Keep reading for free
Create a free CaseChat account to read BioNTech RNA Pharmaceuticals GmbH v CureVac SE and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2023] APO 36
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.